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Defective Tumor Necrosis Factor Release from Crohn’s
Disease Macrophages in Response to Toll-like Receptor
Activation: Relationship to Phenotype and Genome-wide
Association Susceptibility Loci
Gavin W. Sewell, PhD,* Farooq Z. Rahman, PhD,*,† Adam P. Levine, BSc,* Luke Jostins, MPhil,‡
Philip J. Smith, MRCP,* Ann P. Walker, PhD,* Stuart L. Bloom, FRCP,† Anthony W. Segal, PhD, FRS,*
and Andrew M. Smith, PhD*
Background: Recent work provides evidence of a failure of acute inflammation in Crohn’s disease (CD), and suggests that the primary defect
operates at the level of the macrophage and cytokine release. Here we extend the characterization of the innate immune defect in CD by investi-
gating the macrophage response to Toll-like receptor (TLR) agonists and assess potential links between genome-wide association study (GWAS)
susceptibility loci, disease phenotype, and therapeutic regimens on tumor necrosis factor a (TNF) release.
Methods: Peripheral blood-derived macrophages were cultured from control subjects and patients with CD, stimulated with TLR ligands, and
the release of TNF measured. Genomic DNA was purified from blood and genotyped for 34 single nucleotide polymorphisms (SNPs) identified
as being associated with CD by GWAS.
Results: All stimuli resulted in a reduction (32%–48%) in TNF release from macrophages derived from CD patients (n ¼ 28–101) compared to
those from healthy control (HC) subjects. All phenotypes demonstrated impaired TNF release, with the greatest defect in patients with colonic
disease. There was no detectable relationship between the level of TNF released and the presence of GWAS susceptibility loci in CD patients.
Reduced TNF levels were not influenced by age, gender, or use of aminosalicylate (5-ASA) medication.
Conclusions: This study supports the hypothesis of defective proinflammatory cytokine secretion and an innate immunodeficiency in CD.
Abnormal TNF secretion is evident downstream of multiple TLRs, affects all disease phenotypes, and is unrelated to 34 polymorphisms associ-
ated with CD by GWAS.
(Inflamm Bowel Dis 2012;18:2120–2127)
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C rohn’s disease (CD) is a chronic relapsing inflamma-tory disease of the gastrointestinal tract associated
with considerable lifelong morbidity.1 It is characterized by
granulomatous inflammation that most frequently affects
the terminal ileum and colon. The incidence of CD has
risen dramatically since the latter part of the 20th century
for reasons that remain poorly understood.2
A number of genetic and environmental factors have
been associated with CD. Recently, genome-wide association
studies (GWAS) have identified a number of single nucleo-
tide polymorphisms (SNPs) with significantly different allele
frequencies between CD and healthy control (HC) cohorts. It
has been estimated that these susceptibility variants account
for 23% of the total heritability of the disease. Some of the
strongest associations include NOD2, the interleukin (IL)-23
receptor IL-23R, and two genes with roles in autophagy
(ATG16L1 and IRGM).3,4 Many of the CD-associated genes
identified to date appear to have important roles in sensing,
clearance, and propagation of the inflammatory response to
commensal microbiota. However, although many of the loci
are suspected to influence immune system function, the func-
tional variants within each locus and the underlying patho-
genic mechanism remain to be elucidated.
Additional Supporting Information may be found in the online version of this
article.
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Mounting evidence suggests that CD may result from
an innate immunodeficiency.5–7 Although the precise mech-
anisms responsible for this abnormality remain to be deter-
mined, a primary pathogenic defect in the macrophage
response to bacteria has recently been shown. Macro-
phages, the sentinels of the immune system, orchestrate
cellular responses against a complex and diverse range of
intestinal microbial insults via pattern recognition receptors
such as Toll-like receptors (TLRs) and NOD-like receptors
(NLRs).8,9 Macrophage activation through these and other
interconnected but subtly distinct signaling pathways indu-
ces secretion of inflammatory mediators that recruit and
activate other leukocytes from the surrounding microcircu-
lation. It is postulated that the dysregulated macrophage
response to bacteria is central to the pathogenesis of CD. A
number of recent studies have demonstrated impaired lev-
els of macrophage proinflammatory cytokine release,
including tumor necrosis factor-a (TNF), in response to E.
coli stimulation.7,10 Attenuated macrophage proinflamma-
tory cytokine secretion may result in the impaired neutro-
phil recruitment and bacterial clearance observed in
patients with CD. The retention of the undigested bacteria
at sites of ingress was proposed to be the driving force for
the ensuing chronic inflammatory reaction and granuloma-
tous pathology that characterizes CD.6,7
TLRs are transmembrane pathogen pattern recogni-
tion receptors expressed by myelomonocytic and epithelial
cells.11 Each TLR recognizes specific bacterial or viral
components; key TLRs in the response to bacteria include
TLR4, which recognizes lipopolysaccharide (LPS), TLR2,
which recognizes lipoteichoic acid, peptidoglycan and the
synthetic tripalmitoylated lipopeptide PAM3CSK4, and
TLR5, which binds to flagellin.12 Ligand-receptor engage-
ment results in intracellular signaling cascades and the
induction of effector responses important for the innate
immune defense against microbes. The potential relevance
of TLRs in the response to intestinal microbiota is demon-
strated by TLR4 knockout mice, which have earlier and
more pronounced gastrointestinal bleeding than wildtype
mice after administration of dextran sodium sulfate (DSS),
which coincided with increased bacterial translocation and
impaired neutrophil recruitment.13 Differential expression
of TLRs have been documented in biopsy samples from
inflammatory bowel disease (IBD) patients.14,15 A number
of studies have reported associations between TLR4 poly-
morphisms and CD,16 although these were not replicated in
a recent large GWAS meta-analysis.4
TNF, a potent mediator of inflammation and major
target of biological therapy in CD, was chosen as the focus
of this study to assess the acute inflammatory response of
macrophages following microbial stimulation. In the pres-
ent study we compared TNF release from CD and HC mac-
rophages after TLR2, TLR4, and TLR5 activation. In addi-
tion, we used these results in combination with patient
information and SNP genotypes to test for any association
between defective proinflammatory responses, inheritable
risk factors, and disease phenotype.
MATERIALS AND METHODS
Patients
Adult patients with definitive diagnoses of CD con-
firmed using standard diagnostic criteria were recruited from
the Gastroenterology Outpatient Clinic at University College
London Hospitals NHS Foundation Trust (UCLH). None of
the patients studied showed any clinical or biochemical evi-
dence of impaired nutritional state. In some experiments,
patients with ulcerative colitis (UC), a clinically and histopa-
thologically distinct form of IBD, were used as a control
group in addition to healthy subjects. All patients recruited
had Harvey–Bradshaw scores of <3 or partial Mayo score <3
for CD and UC, respectively, both of which have been vali-
dated for assessment of disease activity.17,18 All individuals
were on no medication or on maintenance 5-aminosalicylic
acid (5-ASA) at the time of sample collection (Table 1).
These studies were approved by the Joint UCL/UCLH
Committees on the Ethics of Human Research (02/0324).
Written informed consent was obtained from all volunteers.
No patient was studied more than once in each of the different
sets of experiments.
Macrophage Isolation, Culture, and Stimulation
Peripheral venous blood samples were collected from
subjects into heparinized syringes (5 U/mL). Mononuclear
cells were isolated by differential centrifugation (900g, 30
minutes, 20C) over Lymphoprep (Axis-Shield, Oslo, Norway)
and washed twice with sterile phosphate-buffered saline (PBS)
(Gibco, Paisley, UK) at 300g (5 minutes, 20C). Cells were
resuspended in 10 mL RPMI-1640 medium (Invitrogen, Pais-
ley, UK) supplemented with 100 U/mL of penicillin (Gibco)
and 100 lg/mL streptomycin (Gibco) and 20 mM Hepes
buffer (Sigma-Aldridge, Poole, UK) (RPMI), and plated at a
density of 5  106 cells/mL in 8 cm2 Nunclon Surface tis-
sue culture dishes (Nunc, Roskilde, Denmark). After an initial
culture period of 2 hours at 37C, 5% CO2, the nonadherent
cells were discarded and 10 mL of fresh RPMI supplemented
with 10% fetal bovine serum (Sigma) (10% FBS/RPMI) added
to each tissue culture dish. Cells were then cultured for 5 days
at 37C, 5% CO2, with the addition of a further 10 mL fresh
10% FBS/RPMI after 24 hours.
Adherent cells were scraped on day 5 and replated in
96-well culture plates at equal densities (105/well) in X-Vivo-
15 medium (Cambrex, Walkersville, MD). These primary
monocyte-derived macrophages were incubated overnight at
37C, 5% CO2 to adhere, and then stimulated for up to 24
hours 200 ng/mL LPS (Alexis, San Diego, CA), 2 lg/mL
Pam3-Cys-Lys4 (Alexis) and 20 ng/mL flagellin (Alexis).
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TNF Release After TLR Stimulation
TNF release was measured using a cytotoxicity bioassay
(obtained from Prof. B. Beutler, Scripps Institute, La Jolla,
CA) as previously described.19 Murine L929 fibroblast cells
were grown in Dulbecco’s modified Eagle’s medium (DMEM;
Gibco), supplemented with 10% FBS (Sigma), 100 U/mL of
penicillin (Gibco), and 100 lg/mL streptomycin (Gibco), at
37C, 5% CO2. A confluent monolayer of murine L929 fibro-
blasts was trypsinized and resuspended to 4  105 cells/mL in
DMEM. L929 cells were seeded into 96-well flat-bottom tis-
sue culture plates (4  104 cells/well) and incubated overnight
at 37C, 5% CO2. After overnight culture the medium was
discarded, replaced by 50 lL DMEM containing cyclohexi-
mide (0.04 mg/mL), and incubated for 20 minutes at 37C,
5% CO2. Fifty lL of cell-free supernatant (diluted 1:50 in
DMEM), collected from primary macrophages as described,
was added to individual wells. Serially diluted recombinant
human TNF (R&D Systems, Minneapolis, MN) (100-0 pg/mL)
was used to determine the standard curve for the assay.
Cytokine release in culture supernatants was normalized
for the numbers of viable cells in each well, ascertained with
the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrozo-
lium bromide, tetrazolium salt) assay (Boehringer Ingelheim,
Berkshire, UK). Twenty lL of 2.5 ng/mL MTT was added to
each well and incubated for 4 hours at 37C, 5% CO2. Super-
natants were carefully discarded and 100 lL/well of lysis
solution (90% isopropanol, 0.5% sodium dodecyl sulfate
[SDS], 0.04 N HCl, 10% H20) added to each well for 1 hour
at room temperature. The absorbance was read at 570 nm
using a microplate reader (Anthos Labtec Instruments,
Salzburg, Austria).
Purification of Total Genomic DNA
Peripheral venous blood samples were collected from
subjects into heparinized syringes (5 U/mL) and genomic
DNA prepared, using the QIAamp DNA blood Mini Kit (Qia-
gen, Hilden, Germany). Optical density readings were deter-
mined for OD260/OD280 and OD260/OD230 using a NanoDrop
ND-1000 spectrophotometer (Fisher Scientific, Loughborough,
UK) to assess protein and solvent contamination, respectively.
SNP Genotyping
Genotyping for 34 CD-associated SNPs was performed
using the iPLEX Gold Assay (Sequenom, San Diego, CA),
shown in Supporting Table 1. The SNPs were selected based
on the results of previous GWAS.3 Assays for all SNPs were
designed using the eXTEND suite and MassARRAY Assay
Design software v. 3.1 (Sequenom). Amplification was con-
ducted in a total volume of 5 lL containing 0.06–0.4 ng
genomic DNA, 100 nM of each PCR primer, 500 lM of each
dNTP, 1.25  PCR buffer (Qiagen), 1.625 mM MgCl2, and
1U HotStar Taq (Qiagen). Reactions were heated to 94C for
15 minutes followed by 45 cycles at 94C for 20 seconds,
56C for 30 seconds, and 72C for 1 minute, then a final
extension at 72C for 3 minutes. Unincorporated dNTPs were
shrimp alkaline phosphatase (SAP)-digested prior to iPLEX
Gold allele specific extension with mass-modified ddNTPs
using an iPLEX Gold reagent kit (Sequenom), in accordance
with the manufacturer’s instructions. Reaction extension
primer concentrations were adjusted to between 0.7–1.8 lM,
dependent on primer mass. Extension products were desalted
and dispensed onto a SpectroCHIP using a MassARRAY
Nanodispenser prior to matrix-assisted laser desorption ioniza-
tion time-of-flight (MALDI-TOF) analysis with a MassAR-
RAY Analyzer Compact mass spectrometer. Genotypes were
automatically assigned and manually confirmed using Mas-
sARRAY TyperAnalyzer software v. 4.0 (Sequenom). In a
few cases the genotypes could not be assigned and these indi-
viduals were therefore excluded from the analysis.
Statistical Analysis
All data are presented as mean 6 standard error of the
mean (SEM). Statistical significance between groups was eval-
uated using a one-way analysis of variance (ANOVA) with
Tukey posttest or an unpaired two-tailed Student’s t-test when
only two groups were compared. Mean differences were con-
sidered significant when P < 0.05. Correlation analysis was
assessed using Pearson’s correlation coefficient.
RESULTS
CD Macrophages Release Diminished TNF After
TLR Stimulation
We first determined whether macrophage TNF secre-
tion was defective after various TLR stimuli. Monocyte-
derived macrophages were activated with the TLR ligands
TABLE 1. Demographics of the Subjects
HC CD UC
n 41 101 47
Gender (M:F) 21:20 37:64 24:23
Mean age 32.8 41.6 44.5
Age standard deviation 9.93 15.3 15.9
Age range 20-59 18-75 21-75
Smokers 5 20 3
Treatment
No medication 25
5-ASA only 76
Others 0
Disease location
L1 32
L2 44
L3 24
L4 1
Genotype information 36 97
Disease location was subdivided into ileal (L1), colonic (L2), ileocolonic
(L3), and upper gastrointestinal (L4).
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PAM3CSK4 (HC n ¼ 41 and CD n ¼ 101), LPS (HC n ¼
33 and CD n ¼ 83), and flagellin (HC n ¼ 13 and CD n ¼
28). In all cases macrophages isolated from CD patients
demonstrated grossly attenuated TNF secretion compared
to control subjects (Fig. 1). TLR2 activation by
PAM3CSK4 resulted in macrophages from CD patients
releasing TNF at levels which were equivalent to a 45%
reduction compared to the control group (P ¼ 4  108).
LPS exposure results in TLR4 activation and release of
TNF from CD macrophages, and again this was signifi-
cantly lower than the control group (32%, P ¼ 2  106).
Similarly, TLR5 ligation by flagellin demonstrated attenua-
tion in TNF release (48%, P ¼ 0.003). Reduced TNF
secretion was not due to differences between CD and HC
macrophage phenotype, reduced TLR expression, or abnor-
malities in receptor signaling and gene induction (Support-
ing Fig. 1).7 These results provide evidence to support an
altered macrophage immune response to microbial chal-
lenge in CD and show that the defect is not restricted to an
individual receptor.
Association Between Aberrant TNF Release and
Disease Phenotype
It is now recognized that CD is a syndrome and can
be divided into subtypes depending on disease phenotype,
ileal (L1), colonic (L2), and ileocolonic (L3).20 It was
therefore of interest to subdivide our CD patients into phe-
notypic groups and compare the levels of TNF released
after PAM3CSK4 and LPS stimulation (Fig. 2). All three
phenotypes demonstrated defective TNF secretion com-
pared to HC after stimulation with either PAM3CSK4 or
LPS. Direct comparison between all three CD phenotypes
revealed that L1 patients released higher TNF levels than
L2 patients and this difference reached significance with
LPS (P ¼ 0.047). Therefore, diminished TNF secretion is
common to all three phenotypes and confirms our previous
FIGURE 1. Macrophages from CD patients release attenuated TNF in response to TLR stimulation. Monocyte-derived macrophages stimulated
for 6 hours with PAM3CSK4 (PAM3), LPS, and flagellin, and TNF levels in supernatants were quantified using the TNF bioassay. (A) TLR2 response
was measured in macrophages from HC (n ¼ 41) and CD (n ¼ 101) after PAM3 stimulation. (B) TLR4 response was measured in macrophages
from HC (n ¼ 38) and CD (n ¼ 87) after LPS stimulation. (C) TLR5 response was measured in macrophages from HC (n ¼ 13) and CD (n ¼ 28) af-
ter flagellin stimulation. TNF levels from each subject are depicted with the mean value shown as a black horizontal bar with P-value. Data are
shown on a logarithmic scale. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
FIGURE 2. Defective TNF release is common to all phenotypes. CD
subjects were divided into three phenotypic subgroups based on
disease location, including ileal (L1, n ¼ 32), colonic (L2, n ¼ 44),
and ileocolonic (L3, n ¼ 24) involvement. (A) There were no signifi-
cant differences in macrophage TNF release after TLR2 stimulation
between disease phenotypes. (B) Macrophages from patients with
colonic CD release significantly less TNF than ileal patients after
TLR4 stimulation with LPS. Macrophages from all groups released
significantly less TNF than the HC cohort in response to TLR2 and
TLR4 stimulation. Results expressed as mean 6 SEM with P-value.
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findings demonstrating defective TNF release after E. coli
stimulation in both ileal and colonic patients.7
Abnormal TNF Release Is Not Dependent on Prior
Bowel Inflammation, Gender, Age, or Medication
We examined whether factors such as prior bowel
inflammation, medication, smoking tobacco, age, and gen-
der could have a confounding influence on macrophage
TNF secretion in response to TLR agonists. No correlation
was observed between age and TNF release after either
PAM3CSK4 (r
2 ¼ 0.005, P ¼ 0.94) or LPS (r2 ¼ 0.0164,
P ¼ 0.24) stimulation (Supporting Fig. 2). In addition,
there was no association between current medication,
smoking status, or gender (Fig. 3A–C). Interestingly, CD
patients who smoked released TNF levels that were not
significantly different from HC after LPS stimulation; how-
ever, the same individuals did demonstrate impaired TNF
secretion after PAM3CSK4 exposure (P ¼ 0.002).
In order to determine whether previous bowel inflam-
mation could influence macrophage TNF release, patients
with UC were investigated as an additional control cohort.
Macrophages from UC subjects (n ¼ 47) released TNF at
levels equivalent to HC, and significantly greater than CD
patients after PAM3CSK4 (P ¼ 2  106) and LPS stimu-
lation (P ¼ 3  104) (Fig. 4).
These results demonstrate that the attenuated TNF
release by CD macrophages is attributable to the disease
and independent of previous bowel inflammation, use of 5-
ASA medication, age, or gender. Smoking status seems to
be more complex, with an apparent normal TNF release
downstream of TLR4 in smokers coinciding with a defec-
tive TLR2 response. Further investigation will be necessary
to determine the mechanism of these observations.
FIGURE 3. TNF secretion after TLR2 and TLR4 activation in relation to medical treatment, smoking, and gender. CD patients and where
applicable HC were divided by (A) treatment (CD no-treatment n ¼ 25, 5-ASA treatment n ¼ 76; HC n ¼ 38), (B) smoking (CD smoker
n ¼ 20, nonsmoker n ¼ 81), and (C) gender, (CD male [M] n ¼ 37, female [F] n ¼ 64; HC male [M] n ¼ 21, female [F] n ¼ 20). All results
are expressed as mean 6 SEM with P-value.
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Diminished TNF Secretion Is Not Dependent on
CD Susceptibility Polymorphisms
GWAS have identified over 70 loci that are associated
with CD.3,4 In this study we looked for association between
34 SNPs strongly associated with CD and TNF secretion
downstream of TLR2 (Fig. 5; Supporting Table 1). NOD2 is
the strongest CD-associated gene identified to date, which
encodes an intracellular sensor of muramyl dipeptide
(MDP). The three CD-associated polymorphisms in NOD2
have been shown to result in defective pro- and antiinflam-
matory cytokine induction after stimulation with MDP.21 We
investigated the effect NOD2 polymorphisms had on TNF
release downstream of TLR2 stimulation. Dividing our CD
cohort into patients either homozygous or compound hetero-
zygous (n ¼ 5), heterozygous (n ¼ 16), or wildtype (n ¼ 71)
for NOD2 polymorphisms showed no significant effect on
TNF release after PAM3CSK4 stimulation (Fig. 5A). In addi-
tion, the attenuated TNF release was independent of poly-
morphisms in the autophagy-associated genes ATG16L1 and
IRGM (Fig. 5B,C), and IL-23R (Fig. 5D). The other 28 SNPs
tested also demonstrated no effect on TNF release in HC and
CD cohorts (data not shown). The same findings were also
evident after TLR4 stimulation (data not shown). HC who
carry one NOD2 CD risk allele release levels of TNF equiva-
lent to individuals with two wildtype alleles, whereas one
individual with two risk alleles demonstrated attenuated
TNF levels (Fig. 5E). Furthermore, the release of TNF from
HC macrophages in response to PAM3CSK4 did not differ
significantly between wildtype, heterozygous, or homozy-
gous individuals for ATG16L1, IRGM, or IL-23R CD-associ-
ated polymorphisms (Fig. 5F–H).
These results indicate that there is no detectable rela-
tionship between the highly significant susceptibility loci
identified by GWAS and the defective release of TNF
downstream of TLR activation, with the possible exception
of NOD2, suggesting these could be independent events
that coincide in patients with CD.
DISCUSSION
We present evidence demonstrating that macrophages
from CD patients have attenuated TNF release downstream
of multiple TLRs. This defect was evident in all three major
CD phenotypes, and was not related to use of 5-ASA medi-
cation or previous bowel inflammation. The age and gender
of the patient also had no effect on the levels of TNF
released. The majority of susceptibility loci that have been
identified by large-scale GWAS failed to demonstrate an
influence on TNF release from macrophages after TLR acti-
vation. These results build on the growing body of work
supporting a defective innate immune response in CD, but
highlight our lack of mechanistic insight into the cause of
this abnormality. The lack of association between impaired
TNF release and GWAS risk alleles also reveals that while
both coexist in CD, they are likely independent. Individuals
who are more likely to develop CD may have inherent sus-
ceptibility plus a weak innate immune response.
CD is a complex disease comprising multiple stages
and phenotypes. We recently demonstrated that CD patients
clear bacteria less rapidly than control individuals, which
was associated with delayed recruitment of neutrophils and
defective macrophage function.7 This led us to propose a
‘‘three-stage’’ model for CD pathogenesis—where mucosal
damage and penetration of bacteria and other particulate
matter from the bowel wall is followed by an impaired mac-
rophage response and incomplete bacterial clearance. Subse-
quently, a compensatory adaptive immunological response
develops, associated with chronic, granulomatous inflamma-
tion and an elevation in proinflammatory cytokines that is
characteristic of the ‘‘active’’ phase of CD.22 Our findings
here of defective TNF release by CD macrophages in
response to TLR agonists is consistent with this model,
given the prominent role of TNF in the acute inflammatory
response, upregulation of vascular cellular adhesion mole-
cules,23 and resultant recruitment of neutrophils.
A role for deficient release of TNF in the pathogene-
sis of CD is supported by a number of in vivo studies. The
effect of TNF blockade or deficiency in the DSS murine
model of colitis is particularly instructive. Although antago-
nists of this cytokine are highly effective at ameliorating
inflammation when given to mice with established colitis,
FIGURE 4. Macrophages from UC patients release normal levels of
TNF in response to TLR stimulation. Supernatants from macrophages
stimulated for 6 hours with PAM3 and LPS were tested for the levels
of TNF released. (A) TLR2 response was measured in macrophages
from HC (n ¼ 41), CD (n ¼ 101), and UC (n ¼ 47) after PAM3 stimula-
tion. (B) TLR4 response was measured in macrophages from HC (n ¼
38), CD (n ¼ 87), and UC (n ¼ 47) after LPS stimulation. TNF levels
from each subject are depicted with the mean value shown as a
black horizontal bar with P-value. [Color figure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
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animals with a genetic deficiency of TNF are more suscepti-
ble to acute colitis than wildtype animals, with a 60% 7-day
mortality compared to 0% in control animals.24 The dichot-
omous effects of this pivotal cytokine supports the concept
of the ‘‘phasic’’ nature of CD pathogenesis and suggests
that the same cytokines that have a deleterious effect during
chronic inflammation may confer protection in the preced-
ing acute inflammatory response. Polymorphisms associated
with disease through GWAS are mainly markers of shared
genetic regions that are present at increased frequency in
individuals with disease. The biological roles these markers
play remain largely unknown and to date a number of stud-
ies have been carried out on NOD2, IL23R, and ATG16L1
with contradictory results. NOD2 polymorphisms are asso-
ciated with impaired induction of proinflammatory cyto-
kines in response to MDP,21 yet peripheral blood mononu-
clear cells from individuals with the ATG16L1 Thr300Ala
CD-risk variant were recently reported to release increased
levels of IL-1b after MDP stimulation,25 and ATG16L1 de-
ficient macrophages secrete increased IL-1b and IL-18 in
response to LPS.26 In this study we looked for associations
between CD susceptibility polymorphisms and the defective
release of TNF from macrophages. Overall, the results sug-
gest that the strongest associated polymorphisms play no
major role in the reduced TNF levels associated with mac-
rophages from CD patients. A possible exception is NOD2,
as CD individuals and one HC individual tested demon-
strated a trend toward attenuated TNF release in response to
TLR2 stimulation compared to NOD2 wildtype individuals.
Although studies conducted on macrophages from NOD2
knockout mice revealed normal TNF release in response to
TLR2 activation with peptidoglycan,27 further studies will
be required to clarify the role of NOD2 in the human mac-
rophage TLR2 response.
The results further suggest that the molecular basis of
abnormal proinflammatory cytokine secretion by CD mac-
rophages has not yet been identified and additional studies
are needed to account for this phenomenon. A number of
FIGURE 5. Relationship between TNF secretion after TLR2 activation and GWAS SNPs. Patients were typed for 34 SNPs associated with
increased risk of developing CD and separated into homozygous nonrisk (black), heterozygous (gray), and homozygous risk (white) for (A)
NOD2 (compound heterozygotes where grouped with homozygous risk), (B) IRGM, (C) ATG16L1, and (D) IL23R and the corresponding TNF
levels after TLR2 activation shown. Corresponding results for the HC cohort are shown in (E–H). Results expressed as mean 6 SEM with
P-value, value shown in each bar represents the number of individuals in each genotype.
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additional loci have recently been reported as associated with
CD, several of which contain genes encoding proteins
involved in vesicle and protein trafficking (VAMP3, NDFIP1,
SCAMP3), which could have a role in proinflammatory cyto-
kine release by macrophages. It has been estimated that
23% of the heritability of CD can be explained by the var-
iants identified to date by GWAS.4 Furthermore, it has been
postulated that rare variants, structural rearrangements, or
epigenetic modifications could account for some of the
‘‘missing heritability.’’28 It is very possible that some of these
mutations, which are likely to be highly heterogeneous
between individual CD patients, could be important determi-
nants of the macrophage response to bacterial agonists.
Impairment of TNF release is more severe in patients
with colonic CD. Whereas defective pathways associated
with NOD2 have been implicated in the causation of ileal
CD, a grossly impaired TLR response to bacteria appears
to be more relevant to colonic inflammation in CD. Our
results suggest that future studies on the pathogenesis of
this heterogeneous condition may prove more fruitful if
patients with CD are grouped according to phenotype
rather than by their primary diagnosis. This is an important
consideration when interpreting genome-wide association
projects as well as planning therapeutic regimens and clini-
cal trials. Work to define the precise underlying molecular
defects associated with defective cytokine secretion is
ongoing and may offer novel therapeutic targets in the
future.
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